$AAME

Atlantic American files late 10-Q notice (NASDAQ: AAME) over ASU 2018-12 work

Atlantic American Corporation (NASDAQ: AAME) has filed a Form 12b-25, notifying the SEC of its inability to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The delay is attributed to the need for additional time to compile financial data and supporting documentation related to ASU 2018-12 (Topic 944) for long-duration insurance contracts, and to allow its accounting firm to complete audit and review procedures. The company also needs to finalize its Form 10-K for the year ended December 31, 2025.

Original reporting
Published May 19, 2026, 1:38 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 19, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$AAME
Bearish
medium confidence
Mentioned
$AAME
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$AAMEBearishMed
01

Why it matters

The delay may cause short-term stock price decline and increased volatility, especially among traders reacting to news and sentiment shifts.

02

Market read

The news has moderate relevance for traders focusing on financial disclosures and sector health, with immediate implications for AAME stock.

03

What to watch

Potential for the company to use the delay to strengthen internal controls or prepare for a strategic announcement, which could lead to a positive surprise.

Timing: Immediate, as the filing delay is recent and may influence trading today.

Background

Atlantic American Corporation delayed its quarterly filing due to additional time needed for financial data compilation related to ASU 2018-12, affecting investor confidence.

Company-level read

Ticker impact

$AAMEBearishMedium confidence
Context

High relevance due to direct impact on company's financial reporting and investor perception.

Expected impact

Potential short-term decline of 2-4% due to investor concern over delayed filings.

Evidence & confidence

The recent filing delay coupled with a somewhat-bearish sentiment score suggests cautious trading; however, the impact may be mitigated if the company clarifies the reasons for delay.

Market effects

Potential negative perception of insurance and financial sectors due to delayed disclosures.

Limited regional impact, primarily affecting investor sentiment in the U.S.

Minimal, as the news pertains to a U.S.-listed company with localized effects.

Counterpoint

The delay might be a temporary administrative issue with no material impact on long-term fundamentals; the stock could rebound once the delay is resolved.

Key entities

  • Atlantic American Corporation

    A U.S.-based insurance and financial services company.

Related articles

$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

$EXCMed

Why Exelon's CFO is stepping into a new strategy role

Exelon's CFO Jeanne Jones transitions to a new role as EVP of finance and strategy on Oct. 5, focusing on long-term strategy and capital allocation. Robert Kleczynski will succeed Jones as CFO. Exelon reported Q2 revenue of $5.97 billion, up 10% YoY, beating estimates. The company is investing in infrastructure amid rising electricity demand and pressure to keep customer bills affordable.